NPM1-mutated AML in the absence of FLT3-ITD in CR1 does not derive RFS or OS benefit from allogeneic stem cell transplantation (7, 136) underscoring the chemosensitivity and likely immunogenicity (as discussed below), of this subtype of AML. The gene discussed is NPM1; the disease is acute myeloid leukemia.